Year: 2021

news_6

Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen

Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by...

news_6

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy

First Approval in Japan for the KEYTRUDA Plus LENVIMA Combination KENILWORTH, N.J. & TOKYO--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as...